Benign prostatic hyperplasia (BPH) is a progressive disease commonly associated with bothersome lower urinary tract symptoms (LUTS).
Introduction

BPH patients with lower urinary tract symptoms (LUTS)
under combination therapy were retrospectively analyzed from 1 to 12 years span. The therapeutics effects were assessed by International Prostatic Symptoms Score (IPSS) and quality of life index (QoL-I), total prostatic volume (TPV), maximum flow rate (Qmax), voided volume (VoL), prostatic specific antigen (PSA) at baseline and annually. The reason and predictors of discontinued combination therapy were also investigated.
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A total of 625 patients, aged 40-97 (mean, 73) years, with 1-12 years of follow-up (mean, 3 years) were retrospectively enrolled. All measured parameters showed significant improvement after combination therapy. Three hundred and sixty-nine (59%) patients discontinued combination therapy with mean treatment duration of 2.2 years. The most common reason for discontinuation of combination therapy was conversion to single medication (19.8%). Age and QoL-1 did not influence the adherence rate, but the larger Qmax and larger TPV lead to better adherence to combination therapy.
